{"id":"NCT00129766","sponsor":"MedImmune LLC","briefTitle":"Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children","officialTitle":"A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-11","primaryCompletion":"2006-05","completion":"2006-05","firstPosted":"2005-08-12","resultsPosted":"2013-08-28","lastUpdate":"2013-08-28"},"enrollment":6635,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Syncytial Virus Infections"],"interventions":[{"type":"BIOLOGICAL","name":"motavizumab (MEDI-524)","otherNames":["MEDI-524"]},{"type":"BIOLOGICAL","name":"palivizumab","otherNames":["Synagis"]}],"arms":[{"label":"palivizumab","type":"ACTIVE_COMPARATOR"},{"label":"motavizumab (MEDI-524)","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study was to compare the safety and efficacy of motavizumab to palivizumab when administered monthly by intramuscular (IM) injection for the reduction of the incidence of RSV hospitalization among children at high risk for serious RSV disease. A secondary objective was to compare the incidence of medically-attended lower respiratory infections (LRIs) between treatment groups.","primaryOutcome":{"measure":"Incidence of RSV Hospitalization (Includes Deaths by RSV)","timeFrame":"Days 0 - 150","effectByArm":[{"arm":"Palivizumab","deltaMin":62,"sd":null},{"arm":"Motavizumab","deltaMin":46,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":15},"locations":{"siteCount":344,"countries":["United States","Argentina","Australia","Austria","Brazil","Bulgaria","Canada","Chile","Czechia","Denmark","France","Germany","Greece","Hungary","Iceland","Israel","Italy","New Zealand","Poland","Russia","Spain","Sweden","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["20008423"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":506,"n":3298},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","PYREXIA","RHINITIS","OTITIS MEDIA","TEETHING"]}}